ACH-1625 Phase 1a results (question/comments)
Dew (or others): the PR noted that there were no SAEs in the Phase 1a trial and that adverse events were "mild and transient." I am just curious if it's normal to see adverse events of any kind in a Phase 1a trial for an HCV PI in healthy patients. Perhaps I'm being unduly cautious, but ACHN is one of my largest holdings, and I want to make sure I'm on top of this.
The dose tested in the Phase 1a went up to 2000 mg/day, which I assume is well above what will be tested in HCV patients in the Phase 1b given the potency of ACH-1625.
Market Data 
Markets 
AI
